Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy

Journal of Heart and Lung Transplantation

Volumn 37, Issue 2, 2018, Pages 268-274

  Leuschner, Gabriela ^a,b   Stocker, Florian ^a   Veit, Tobias ^a,b   Kneidinger, Nikolaus ^a,b   Winter, Hauke ^b,c   Schramm, René ^b,c   Weig, Thomas ^b,c   Matthes, Sandhya ^a,b   Ceelen, Felix ^a,b   Arnold, Paola ^a,b   Munker, Dieter ^a,b   Klenner, Friederike ^a,b   Hatz, Rudolf ^b,c   Frankenberger, Marion ^d   Behr, Jürgen ^a,b   Neurohr, Claus ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Lung Transplant Group   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

anti fibrotic therapy; idiopathic pulmonary fibrosis; lung transplantation; nintedanib; pirfenidone; post operative complications

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PIRFENIDONE;

ADULT; AGE; ANASTOMOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG DIFFUSION CAPACITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; SURVIVAL; WOUND HEALING;

EID: 85024859484     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2017.07.002     Document Type: Article

References (24)

1. Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
3. Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
4. King, T.E. Jr, Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
5. Karimi-Shah, B.A., Chowdhury, B.A., Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med 372 (2015), 1189–1191.
6. Weill, D., Benden, C., Corris, P.A., et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 34 (2015), 1–15.
7. Lehtonen, S.T., Veijola, A., Karvonen, H., et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res, 17, 2016, 14.
8. Conte, E., Gili, E., Fagone, E., et al. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58 (2014), 13–19.
9. European Medicines Agency. Committee for Medicinal Products assessment report: Esbriet (pirfenidone). 2017, EMA, London.
10. Hilberg, F., Roth, G.J., Krssak, M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68 (2008), 4774–4782.
11. European Medicines Agency. Ofev: European public assessment report—product information. 2017, EMA, London.
12. Wollin, L., Wex, E., Pautsch, A., et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45 (2015), 1434–1445.
13. Ranpura, V., Hapani, S., Wu, S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305 (2011), 487–494.
14. Ley, B., Ryerson, C.J., Vittinghoff, E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
15. Egan, T.M., Murray, S., Bustami, R.T., et al. Development of the new lung allocation system in the United States. Am J Transplant 6 (2006), 1212–1227.
16. Neurohr, C., Huppmann, P., Thum, D., et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 23 (2010), 887–896.
17. Neurohr, C., Huppmann, P., Zimmermann, G., et al. Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation. Transpl Int 22 (2009), 635–643.
18. Christie, J.D., Carby, M., Bag, R., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24 (2005), 1454–1459.
19. Stewart, S., Fishbein, M.C., Snell, G.I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26 (2007), 1229–1242.
20. Estenne, M., Maurer, J.R., Boehler, A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002), 297–310.
21. Verleden, G.M., Raghu, G., Meyer, K.C., et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 33 (2014), 127–133.
22. Delanote, I., Wuyts, W.A., Yserbyt, J., et al. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med, 16, 2016, 156.
23. Egan, T.M., Edwards, L.B., Effect of the lung allocation score on lung transplantation in the United States. J Heart Lung Transplant 35 (2016), 433–439.
24. Hayanga, J.A., Lira, A., Vlahu, T., et al. Lung transplantation in patients with high lung allocation scores in the US: evidence for the need to evaluate score specific outcomes. J Transplant, 2015, 2015, 836751.